The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
but dave actually dave feldman has a study ongoing now uh with matt bouditch i think is his name i'm probably butchering the name of the cardiac radiologist who's doing the ctas but they have two cohorts one is just a regular cohort or and one is a cohort of lean mass hyper responders and they're comparing with ctas over the course of a year to see how much the atherosclerosis progresses
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
dave feldman's group has a really interesting imaging study going on right now there's no data from that study but we will have data in the next few years what they are doing is looking at coronary imaging i believe by ct coronary angiography of patients with quote unquote elevated ldl most of these people are lean mass hyper responders so they have very elevated ldls while remaining insulin sensitive with high hdl low triglycerides this is dave feldman's lipid triad